What is the risk of malignancy index (RMI) for ovarian cancer?

David A. Fishman, MD on behalf of The Mount Sinai Health System

Gynecologic Oncology

Risk of malignancy index (RMI) is a tool currently being used in women who have no symptoms of ovarian cancer. It allows patients who are more likely to have epithelial ovarian cancer to be triaged into a group that would be seen by a gynecologic oncologist compared with patients with a lower probability of malignancy. Those patients would be managed by a practitioner without advanced training.

RMI is obtained by multiplying serum cancer antigen 125 (CA125) levels in U/mL, by a score given for specific pelvic ultrasound findings, and by a score given for menopausal status.

Continue Learning about Ovarian Cancer

When You Should Have an Ovarian Cancer Screening

In the United States unnecessary medical tests and procedures are a trillion, billion dimes a dozen. The Lown Institute says up to $800 billion a year...

Cancer Treatment Centers of America (CTCA)

There are more than 30 ovarian cancer types. They are grouped into three categories based on where t...

David A. Fishman, MD

Cancer antigen 125 (CA125) is physiologically expressed in epithelial tissues. Examples of these...

How Are the Funds Distributed at Overian Cancer Research Fund?

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.